UNIVERSAL ASSEMBLY PLATFORM

What this means for you

Approved and waiting on proof of use. It will register unless the applicant drops it, and its 20 Dec 2024 filing date already counts against anyone who files later.

Record

Serial number

79416426

Mark type

Stylized text

Filed

20 Dec 2024

Attorney of record

Matthew A. Homyk

Goods and services

• Class 001 — Chemicals: Chemicals for use in industry and science; proteins for use in science; proteins for use in industry; proteins for detecting antibodies, other than for medical use; proteins for binding antibodies, other than for medical use; immunological antibodies, other than for medical use; biological preparations for use in industry and science; chemical preparations for use in the biotechnological industry; chemicals for use in the pharmaceutical industry; chemical preparations for use in the production of drugs; chemicals for use in scientific research, other than medical or veterinary purposes; chemicals for use in biotechnological product development
• Class 005 — Pharmaceuticals: Pharmaceuticals and medical preparations for the prevention and treatment of cancer in humans and animals; pharmaceutical drugs for the prevention and treatment of cancer in humans and animals; pharmaceutical preparations for the prevention and treatment of cancer in humans and animals; antibodies for medical purposes; pharmaceutical products for the treatment of cancer; pharmaceutical preparations and substances for the treatment of cancer; pharmaceutical preparations and substances for the prevention of cancer; anti-cancer drugs; biopharmaceuticals for the treatment of cancer; biological preparations for the treatment of cancer; pharmaceutical preparations for the treatment of tumours; chemotherapeutics; biotechnological preparations for medical use for the treatment of cancer
• Class 042 — Scientific and technological services: Scientific and technological services, namely, research and design relating thereto in the fields of pharmaceutical, biomedical, and chemical sciences; drug discovery services; pharmaceutical drug development services; pharmaceutical products development; development of pharmaceutical preparations and medicines; pharmaceutical research and development; research and development for the pharmaceutical industry; scientific research in the nature of conducting clinical trials for others in the field of pharmaceutical products; testing of pharmaceuticals; biochemistry drug services, namely, pharmaceutical drug development services; biotechnology research; biological research, clinical research in the field of radiology and chemotherapy and medical research; research and development in the field of vaccines and medicines; scientific research for medical purposes in the area of cancerous diseases; research and development services in the field of antibodies; research and development in the pharmaceutical and biotechnology fields; biotechnology research, namely, biotechnology testing; scientific research relating to biotechnology; biochemistry consultancy; biochemistry research services; biochemical research and development; research and development in the field of biotechnology; biochemical engineering services; veterinary research laboratory services; medical research laboratory services; medical research laboratory services relating to pharmaceuticals; providing information relating to scientific research in the fields of biochemistry and biotechnology; consultancy in the field of pharmaceutical research; scientific consultancy in the field of biotechnology; consultancy relating to research and development in the field of therapeutics

Owner

• Valink Therapeutics Inc., DE, US
• Valink Therapeutics Inc., US

Prosecution history

• 01 Apr 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
• 10 Mar 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
• 09 Mar 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
• 09 Mar 2026 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
• 02 Dec 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
• 02 Dec 2025 — NON-FINAL ACTION E-MAILED
• 02 Dec 2025 — NON-FINAL ACTION WRITTEN
• 11 Nov 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
• 11 Nov 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
• 11 Nov 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
• 23 Aug 2025 — REFUSAL PROCESSED BY IB
• 02 Aug 2025 — NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
• 02 Aug 2025 — REFUSAL PROCESSED BY MPU
• 04 Jul 2025 — CHANGE OF NAME/ADDRESS REC'D FROM IB
• 13 Jun 2025 — NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW